Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models.
暂无分享,去创建一个
[1] Paul E. Verweij,et al. In Vitro Drug Interaction Modeling of Combinations of Azoles with Terbinafine against Clinical Scedosporium prolificans Isolates , 2003, Antimicrobial Agents and Chemotherapy.
[2] J. Meis,et al. In Vitro Synergistic Interaction between Amphotericin B and Pentamidine against Scedosporium prolificans , 2002, Antimicrobial Agents and Chemotherapy.
[3] M. Bergervoet,et al. In Vitro Interaction of Flucytosine Combined with Amphotericin B or Fluconazole against Thirty-Five Yeast Isolates Determined by both the Fractional Inhibitory Concentration Index and the Response Surface Approach , 2002, Antimicrobial Agents and Chemotherapy.
[4] J. Meis,et al. Methodological issues related to antifungal drug interaction modelling for filamentous fungi , 2002 .
[5] J. Meis,et al. Comparison of Fractional Inhibitory Concentration Index with Response Surface Modeling for Characterization of In Vitro Interaction of Antifungals against Itraconazole-Susceptible and -Resistant Aspergillus fumigatus Isolates , 2002, Antimicrobial Agents and Chemotherapy.
[6] M. Ghannoum,et al. Antifungal Susceptibility Testing: Practical Aspects and Current Challenges , 2001, Clinical Microbiology Reviews.
[7] D. Kontoyiannis,et al. Itraconazole-Amphotericin B Antagonism inAspergillus fumigatus: an E-Test-Based Strategy , 2000, Antimicrobial Agents and Chemotherapy.
[8] J. Bilello,et al. Use of Drug Effect Interaction Modeling with Monte Carlo Simulation To Examine the Impact of Dosing Interval on the Projected Antiviral Activity of the Combination of Abacavir and Amprenavir , 2000, Antimicrobial Agents and Chemotherapy.
[9] J. Bilello,et al. The Triple Combination Indinavir-Zidovudine-Lamivudine Is Highly Synergistic , 2000, Antimicrobial Agents and Chemotherapy.
[10] S. Katiyar,et al. Antagonism of Azole Activity against Candida albicans following Induction of Multidrug Resistance Genes by Selected Antimicrobial Agents , 1999, Antimicrobial Agents and Chemotherapy.
[11] A. Polak. The past, present and future of antimycotic combination therapy , 1999, Mycoses.
[12] J. Bilello,et al. Nucleoside Analog 1592U89 and Human Immunodeficiency Virus Protease Inhibitor 141W94 Are Synergistic In Vitro , 1998, Antimicrobial Agents and Chemotherapy.
[13] A. Patick,et al. Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro , 1997, Antimicrobial agents and chemotherapy.
[14] F. Barchiesi,et al. In vitro activities of terbinafine in combination with fluconazole and itraconazole against isolates of Candida albicans with reduced susceptibility to azoles , 1997, Antimicrobial agents and chemotherapy.
[15] D S Burgess,et al. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test , 1996, Antimicrobial agents and chemotherapy.
[16] V. Yu,et al. In vitro evaluation of combination of fluconazole and flucytosine against Cryptococcus neoformans var. neoformans , 1995, Antimicrobial agents and chemotherapy.
[17] J. Peter,et al. Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii , 1995, Antimicrobial agents and chemotherapy.
[18] W. Greco,et al. The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.
[19] K. Hara,et al. Effects of antifungal agent combinations administered simultaneously and sequentially against Aspergillus fumigatus , 1994, Antimicrobial Agents and Chemotherapy.
[20] J. Galgiani,et al. Antifungal susceptibility testing. , 2006, Infectious disease clinics of North America.
[21] M. Prichard,et al. Strategic design and three-dimensional analysis of antiviral drug combinations , 1993, Antimicrobial Agents and Chemotherapy.
[22] J Sühnel,et al. Zero interaction response surfaces, interaction functions and difference response surfaces for combinations of biologically active agents. , 1992, Arzneimittel-Forschung.
[23] J. Sühnel. Re: W. R. Greco et al., Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. Cancer Res., 50: 5318-5327, 1990. , 1992, Cancer research.
[24] M. Nassiri,et al. Three-dimensional analysis of the synergistic cytotoxicity of ganciclovir and zidovudine , 1991, Antimicrobial Agents and Chemotherapy.
[25] M. Prichard,et al. A three-dimensional model to analyze drug-drug interactions. , 1990, Antiviral research.
[26] W R Greco,et al. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. , 1990, Cancer research.
[27] D Z D'Argenio,et al. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. , 1990, Mathematical biosciences.
[28] Berenbaum Mc. What is synergy? , 1989, Pharmacological reviews.
[29] W. H. Carter,et al. The evaluation of biological interactions using response surface methodology , 1987, Cell Biology and Toxicology.
[30] M. Berenbaum,et al. Minor synergy and antagonism may be clinically important. , 1987, The Journal of antimicrobial chemotherapy.
[31] A. Galloway. Antibiotics in catheterized patients. , 1987, The Journal of antimicrobial chemotherapy.
[32] J. Hamilton-miller. Rationalization of terminology and methodology in the study of antibiotic interaction. , 1985, The Journal of antimicrobial chemotherapy.
[33] F. Odds. Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro , 1982, Antimicrobial Agents and Chemotherapy.
[34] S. W. Holmes,et al. Antibacterial properties of alafosfalin combined with cephalexin , 1981, Antimicrobial Agents and Chemotherapy.
[35] Larson He. Antimicrobial Agent-Induced Colitis , 1980 .
[36] M. Berenbaum,et al. Correlations between methods for measurement of synergy. , 1980, The Journal of infectious diseases.
[37] C. Norden,et al. Comparison of techniques for measurement of in vitro antibiotic synergism. , 1979, The Journal of infectious diseases.
[38] M C Berenbaum,et al. Synergy, additivism and antagonism in immunosuppression. A critical review. , 1977, Clinical and experimental immunology.
[39] B. Drewinko,et al. Combination chemotherapy in vitro with cis-dichlorodiammineplatinum(II). , 1976, Cancer treatment reports.
[40] V. Lorian. Antibiotics in laboratory medicine , 2005 .
[41] Chase Pa. The search for synergy. , 1997 .
[42] W. Greco,et al. Combined action of paclitaxel and cisplatin against wildtype and resistant human ovarian carcinoma cells , 1997, Cancer Chemotherapy and Pharmacology.
[43] Wampler Gl,et al. Review of the application of response surface methodology in the combination therapy of cancer , 1986 .